Population
/HER2− metastatic breast cancer
In this national, multicentric, randomized, open-label phase II study, patients had to have progressed on endocrine therapy and one or two lines of chemotherapy for HR + /HER2− metastatic breast cancer. Inclusion criteria were: age ≥ 50 years, post-menopausal woman, ECOG performance status (PS) 0, 1 or 2, adequate biological function (polynuclear neutrophils ≥ 1,5.10